Emerging Drugs for the Treatment of Alopecia Areata

Alopecia Areata (AA) is a prevalent non-scarring hair loss disorder affecting 1 in 1000 people globally, with a lifetime incidence of 2%. Despite the availability of treatments, no therapy guarantees permanent remission or universal hair regrowth, particularly in severe cases. Recently, oral baricitinib has been approved as the first drug specifically for AA. The review highlights that while new and effective drugs are emerging, they are not universally effective, and recurrence rates remain high after treatment cessation. AA significantly impacts quality of life and should be treated as a systemic disease, considering comorbidities.